Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 15/20 | 0.59 |
| ▸ | MC3R | P41968 | 4/20 | 0.47 |
| ▸ | UGCG | Q16739 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | MC5R | P33032 | 2/20 | 0.41 |
| ▸ | MC1R | Q01726 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6736765 | 1.00 | MC4R (0.59) | MC4RMC3RUGCGCYP3A4KDM4E | |
| SCHEMBL6736763 | 1.00 | MC4R (0.59) | MC4RMC3RUGCGCYP3A4KDM4E | |
| SCHEMBL6735971 | 0.94 | MC4R (0.53) | MC4RMC3RUGCGCYP3A4KDM4E | |
| SCHEMBL6922986 | 0.94 | MC4R (0.53) | MC4RMC3RUGCGCYP3A4KDM4E | |
| SCHEMBL6737704 | 0.91 | MC4R (0.50) | MC4RMC3RUGCGCYP3A4KDM4E | |
| SCHEMBL6739684 | 0.90 | MC4R (0.60) | MC4RMC3RUGCGCYP3A4ALDH1A1 | |
| SCHEMBL6739687 | 0.90 | MC4R (0.60) | MC4RMC3RUGCGCYP3A4ALDH1A1 | |
| SCHEMBL6739689 | 0.90 | MC4R (0.60) | MC4RMC3RUGCGCYP3A4ALDH1A1 | |
| SCHEMBL6738398 | 0.89 | MC4R (0.58) | MC4RMC3RUGCGCYP3A4ALDH1A1 | |
| SCHEMBL6738395 | 0.89 | MC4R (0.58) | MC4RMC3RUGCGCYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192676-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004058735-A2 | LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192676-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | MC3R, MC1R, MC2R | MC4R 5/4885MC3R 1/4885UGCG 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.